Fisher & Paykel Healthcare Corporation Limited Stock OTC Markets

Equities

FSPKF

NZFAPE0001S2

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 03:49:15 2024-05-28 pm EDT 5-day change 1st Jan Change
16.43 USD +1.80% Intraday chart for Fisher & Paykel Healthcare Corporation Limited +1.80% +16.44%
Sales 2024 1.74B 1.07B Sales 2025 * 1.99B 1.22B Capitalization 16.15B 9.9B
Net income 2024 133M 81.52M Net income 2025 * 347M 213M EV / Sales 2024 8.59 x
Net Debt 2024 * 174M 106M Net Debt 2025 * 238M 146M EV / Sales 2025 * 8.26 x
P/E ratio 2024
113 x
P/E ratio 2025 *
47.9 x
Employees 6,420
Yield 2024 *
1.42%
Yield 2025 *
1.64%
Free-Float 91.12%
More Fundamentals * Assessed data
Dynamic Chart
Fisher & Paykel Healthcare's Net Profit Nearly Halves in Fiscal Year 2024; Shares Rise 6% MT
Transcript : Fisher & Paykel Healthcare Corporation Limited, 2024 Earnings Call, May 29, 2024
New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask MT
Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea MT
JPMorgan Upgrades Fisher & Paykel Healthcare to Neutral from Underweight; Price Target is NZ$24.00 MT
New Zealand Shares Jump on Rate Cut Hopes; WasteCo Raises NZ$3 Million from Convertible Bond Offer MT
Fisher & Paykel Issues Limited Recall of Airvo Devices; Flags NZ$12 Million Hit MT
Fisher & Paykel Healthcare Corporation Limited Initiates Voluntary Limited Recall of Airvo 2 and myAirvo 2 Devices Manufactured Before 14 August 2017 CI
Fisher & Paykel Healthcare Expects NZ$1.73 FY Billion Operating Revenue MT
Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024 CI
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare Corporation Limited Announces Board Changes CI
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to NZ$24.12 From NZ$23.12, Keeps at Equalweight MT
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to AU$22.19 From AU$21.50, Keeps at Equalweight MT
More news

Latest transcript on Fisher & Paykel Healthcare Corporation Limited

1 day+1.80%
1 week+1.80%
Current month+1.80%
1 month+1.80%
3 months+12.53%
6 months+30.92%
Current year+16.44%
More quotes
1 week
16.43
Extreme 16.43
16.43
1 month
16.43
Extreme 16.43
16.43
Current year
14.00
Extreme 14
16.43
1 year
12.00
Extreme 12
16.43
3 years
10.24
Extreme 10.24
24.06
5 years
9.71
Extreme 9.71
26.46
10 years
3.92
Extreme 3.92
26.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 84-12-31
Director of Finance/CFO - 19-02-28
Chief Tech/Sci/R&D Officer - 06-12-31
Members of the board TitleAgeSince
Director/Board Member 66 90-04-30
Chairman - 15-09-30
Chief Executive Officer 63 84-12-31
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, May 28, 2024 at 03:49 pm EDT

More quotes
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Company’s products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India and others.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
27.66 NZD
Average target price
24.65 NZD
Spread / Average Target
-10.88%
Consensus